- Ministry of Health — Ministerio de Salud (Minsa)
Sets national medical cannabis policy under Ley 30681 (2017). Oversees DIGEMID and the implementation of medical cannabis regulations. Peru legalized medical cannabis in 2017.
- National cannabis policy under Ley 30681
- Oversight of DIGEMID pharmaceutical regulation
- Patient access guidelines
- DIGEMID — Dirección General de Medicamentos, Insumos y Drogas
General Directorate of Medicines, Supplies and Drugs. Primary regulatory authority for medical cannabis. Issues import authorizations, manufacturing licenses, and GMP certification.
- Import authorization per shipment
- Manufacturing and GMP certification
- Product registration for domestic market
- Cannabis-specific regulations under Ley 30681
- Licensed Producers — Growing domestic sector
Peru's domestic cannabis production sector is growing. Licensed producers operate under DIGEMID oversight. Several companies now cultivate and manufacture for both domestic and export markets.
- DIGEMID manufacturing license
- GMP certification (BPM / DIGEMID GMP)
- GACP certification for cultivation sites
- Pharmacies — Licensed pharmacies
Medical cannabis dispensed through licensed pharmacies against medical prescription. Peru permits both pharmaceutical-grade and magistral preparation pathways.
- Pharmacy license
- Controlled substance handling protocols
- Medical prescription required
- Patients — Medical cannabis patients
Patients access medical cannabis through medical prescription. Ley 30681 permits use for specified therapeutic indications.